Erasca partners with Merck to test ERAS-0015 and KEYTRUDA combo for RAS-mutant cancers

Erasca announced a clinical trial collaboration with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, combined with Merck's KEYTRUDA (pembrolizumab) for treating RAS-mutant solid tumors. The study, called AURORAS-1, aims to improve treatment outcomes by targeting the RAS/MAPK pathway and enhancing immune response. Merck will supply KEYTRUDA at no cost, while Erasca sponsors the trial. This collaboration targets a large patient population with limited effective therapies and hopes to overcome resistance mechanisms in RAS-driven cancers.